Literature DB >> 2958519

Nonpigmenting fixed drug eruption as a distinctive reaction pattern: examples caused by sensitivity to pseudoephedrine hydrochloride and tetrahydrozoline.

W B Shelley1, E D Shelley.   

Abstract

Nonpigmenting fixed drug eruption is a distinctive, clinically recognizable entity. Characteristically, the lesions are large, symmetrical, well-circumscribed tender erythematous plaques that suddenly appear and reappear in exactly the same sites. They fade without pigmentation or any other trace over a 2- to 3-week period. Management requires recognition and avoidance of the responsible drug. Acute attacks may call for short-term systemic steroid therapy. Three examples of this overlooked reaction pattern are presented. The first case was associated with Night-Time cold formula and was proved by specific component challenge to be due to d-pseudoephedrine hydrochloride. The second case was due to PediaCare 3 Children's Cough Syrup, also containing d-pseudoephedrine hydrochloride. The third case was due to Visine eye drops, which contain an imidazole derivative, tetrahydrozoline. There is a need to increase our awareness that fixed drug eruptions come in two very different clinical forms: the classic pigmenting asymmetrical form, and the nonpigmenting symmetrical erythematous plaque form, in both of which the patient will give a history of the eruption being recurrent in the same area.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2958519     DOI: 10.1016/s0190-9622(87)70220-5

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

Review 1.  Fixed drug eruption: a prototypic disorder mediated by effector memory T cells.

Authors:  Yoshiko Mizukawa; Tetsuo Shiohara
Journal:  Curr Allergy Asthma Rep       Date:  2009-01       Impact factor: 4.806

2.  Co-occurrence of Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) and Pigmented Fixed Drug Eruption (FDE) in a Single Patient Due to Doxycycline: A Case Report.

Authors:  Kananbala Sahu; Chandra S Sirka; Swetalina Pradhan; Arpita N Rout
Journal:  Indian Dermatol Online J       Date:  2020-01-13

3.  Mucosal fixed drug eruption in a patient treated with ornidazole.

Authors:  Charu Mohan Marya; Gaurav Sharma; Vijay P Parashar; Vandana Dahiya
Journal:  J Dermatol Case Rep       Date:  2012-03-27

4.  Clinical Features and Drug Characteristics of Patients with Generalized Fixed Drug Eruption in the West of Iran (2005-2014).

Authors:  Hossein Kavoussi; Mansour Rezaei; Katayoun Derakhshandeh; Alireza Moradi; Ali Ebrahimi; Harif Rashidian; Reza Kavoussi
Journal:  Dermatol Res Pract       Date:  2015-12-10

5.  Clinical features of fixed drug eruption at a tertiary hospital in Korea.

Authors:  Jae-Woo Jung; Sang-Heon Cho; Kyu-Han Kim; Kyung-Up Min; Hye-Ryun Kang
Journal:  Allergy Asthma Immunol Res       Date:  2014-03-26       Impact factor: 5.764

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.